Test Price
900 AED✅ Home Collection Available
Breast Biopsy Panel: ER/PR Hormone Receptor Analysis (Modified Radical Mastectomy)
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity – ISO 15189:2012 Accredited Digital Pathology Core Facility with AI-Enhanced Quantitative Immunohistochemistry. This panel delivers the definitive ER/PR Allred score required for endocrine therapy planning following modified radical mastectomy. Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval from the surgical facility to our ISO-certified cold-chain laboratory. Archival formalin-fixed paraffin-embedded blocks are accepted with completed DHA pathology request form. Clinical Guidance: Complimentary telephonic post-test result explanation by a Specialist Diagnostic Radiologist with breast imaging expertise. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This histopathological panel quantifies estrogen receptor (ER) and progesterone receptor (PR) expression on tissue obtained from a modified radical mastectomy, providing the definitive molecular subtyping essential for endocrine therapy planning. The assay uses ASCO/CAP-compliant quantitative immunohistochemistry (IHC) with digital AI scoring on the Ventana Benchmark Ultra platform, generating an Allred score (0–8 scale) with sub-5% inter-observer variability.
| Feature | Our DHA Panel | Standard Alternative |
|---|---|---|
| Precision | Quantitative AI-aided IHC with digital Allred score (0–8 scale) | Manual semi-quantitative scoring; higher inter-observer variability |
| Methodology | IHC with Ventana Benchmark Ultra, dual ER/PR clones, ISO 17043 proficiency | Conventional IHC without automated digital quantitation |
| Turnaround | 6 days from receipt of formalin-fixed block | 7–14 days |
| Clinical Correlation | Integrated specialist tele-consult | Report only; no guided interpretation |
Physician Insight & Safety Protocols
“As a Specialist in Diagnostic Radiology with focused training in breast imaging, I confirm that this ER/PR IHC panel delivers a reproducible quantitative Allred score with high analytical sensitivity. The result must be integrated with the full surgical pathology report, menopausal status, and mammographic or ultrasound findings. A negative receptor status does not entirely exclude hormone-sensitive disease; clinical-pathologic correlation remains mandatory for accurate therapeutic decision-making.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Therapeutic Advisory
Do not discontinue any prescribed endocrine therapy—including tamoxifen, aromatase inhibitors, or other oncologic medications—based solely on this test result. Treatment modifications must be discussed with your managing oncologist after full review of the histopathology and clinical staging.
Exclusion Criteria & Clinical Red Flags
- Insufficient viable tumor tissue in the paraffin block (< 50 invasive tumor cells)
- Decalcified specimens (Bouin’s fixative or strong acid treatment)
- Active breast infection or seroma requiring surgical drainage prior to block retrieval
- Known anaphylaxis to monoclonal antibodies used in the IHC detection system
- Seek emergency care if: post-biopsy fever > 38°C, expanding hematoma, or signs of systemic infection
Patient FAQ & Clinical Guidance
1. Why do I need ER/PR testing after a mastectomy?
This test determines whether your breast cancer cells express receptors for estrogen or progesterone. The result directly guides whether hormone-blocking therapy—such as tamoxifen or letrozole—will be effective in reducing recurrence risk.
2. How accurate is the ER/PR result, and can it change over time?
The quantitative AI-assisted IHC method achieves > 99% concordance with central reference laboratories. Receptor status can shift with tumor progression or after neoadjuvant therapy; re-biopsy may be advised for recurrent or metastatic disease to guide updated treatment.
3. Will this test tell me if I carry a BRCA gene mutation?
No. This panel exclusively evaluates hormone receptor proteins within the tumor tissue. Assessment of hereditary breast cancer risk requires a separate germline genetic test (BRCA1/BRCA2) on a blood sample.
UAE Regulatory & Data Privacy Adherence
Data Protection. All patient data and diagnostic results are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety, informed consent, and patient rights adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Oversight. DNA Labs UAE operates under DHA Facility License No. 1143 and participates in external quality assessment schemes aligned with international standards for diagnostic histopathology and immunohistochemistry.
Clinical & Logistical Metadata
| Test Name | Breast Biopsy Panel: ER/PR Hormone Receptor Analysis (Modified Radical Mastectomy) |
| Price (AED) | 900 |
| Turnaround Time | 6 Days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block (Archival Specimen) |
| Methodology Used | Quantitative Immunohistochemistry (IHC) with AI-Assisted Digital Scoring (Allred Score) |
| ICD-10-CM Code | C50.919 |
| LOINC Code | 16112-5 |
| DHA Facility License & Laboratory Address | DNA Labs UAE | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians